The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US, answers the question: Is autologous-allogeneic (auto-allo) superior to autologous-autologous (auto-auto) tandem transplant in multiple myeloma (MM)?
Luciano J Costa presents a pooled analysis of four large trials evaluating tandem transplant in MM in over 13,000 patients. Though there was a higher non-relapse mortality with allo-transplant, there was a lower risk of progression and survival after progression was also much higher in patients who previously received allo-transplant. Though this will likely not change the use of allo-transplant in myeloma, Dr Costa highlights that studies comparing auto and allo require long-term follow-up